FindTrial
Sign In

Comparison of two different dosing regime of drug misoprostol for softening of cervix among women undergoing hysteroscopy to visualize inside uterus.

Comparison of two different dosing regime of vaginal misoprostol for cervical priming among women undergoing vaginoscopic hysteroscopy: â??A double blinded randomized controlled trialâ??.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/11/029187
Enrollment
120
Registered
2020-11-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N926- Irregular menstruation, unspecified

Interventions

Intervention1: two different dosing regime of vaginal misoprostol: we will give one dose of 100 microgram misoprostol vaginaly for one study group AND 200 microgram misoprostol vaginaly for other gr

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1.Age more than 18 years 2.Women undergoing diagnostic vaginoscopic hysteroscopy.

Exclusion criteria

Exclusion criteria: EXCLUSION CRITERIA 1.Contraindications to vaginoscopy hysteroscopy- known marked cervical stenosis, recent or current pelvic inflammatory disease, known cervical malignancy, pregnancy, profuse uterine bleeding, or recent uterine perforation. 2.Contraindications to Prostaglandins- known sensitivity to prostaglandins, cardiovascular disease, hypertension, severe bronchial asthma, renal failure, or glaucoma. 3.Previous cervical surgery. 4.Neurological disorders affecting the evaluation of pain.

Design outcomes

Primary

MeasureTime frame
1.Ease of cervical entry by Likert scale. (1-5) Timepoint: Ease of entry assessed by operating surgeon,while negotiating hysteroscope via cervix.—

Secondary

MeasureTime frame
1.Pain perception by VAS. 2.Procedural entry time. 3.Occurrence of side effects. Timepoint: pain assessed at entry of scope,after procedure and half an hour after procedure.entry time assessed from identification of external os to visualisation of uterine cavity.side effects assessed at drug administration and 1 hour after.—

Countries

India

Contacts

Public ContactDr Dilip Kumar Maurya

Department of obstetrics and gynaecology,JIPMER Dhanvanrhari nagar,Puducherry-605006

dilipkm2@gmail.com9442136037

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026